Special Report
Every December, generic and biosimilar teams across Asia Pacific sit down to fix their launch calendars for the coming year. The regulatory side of that ex...
November 18, 2026 | Analysis
Openings in this region arrive with ceremony. There is a groundbreaking, a ribbon, a minister and a press release with a capacity figure in the headline. E...
November 18, 2026 | Analysis
For most of the last two decades, a year in drug approvals could be summarised in a single number: how many new molecular entities the US Food and Drug Adm...
November 17, 2026 | Analysis
The record, counted to 14 November 2026. Method What counts An FDA Breakthrough Therapy designation disclosed by the sponsor or a licensee i...
November 16, 2026 | Analysis
Every capacity plan written in an Asian biopharma company this quarter rests on a calendar it did not write. Somewhere in the spreadsheet is an assumption ...
November 10, 2026 | News
33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refrac...
November 09, 2026 | News
Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...
November 05, 2026 | Analysis
Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...
November 03, 2026 | Regulatory
InventisBio Co., Ltd. announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key seconda...
November 03, 2026 | News
Nuance Pharma announced that the first patient has been dosed in the REACH Phase III clinical trial evaluating STG320 (Actair®) for the treatment of ho...
November 03, 2026 | News
Japan's off-year drug price revision stopped being a question of whether some time ago. When the health and finance ministers closed the FY2026 budget roun...
October 29, 2026 | Analysis
Akeso, Inc. announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration wit...
October 23, 2026 | News
Ask a regulatory affairs lead in Tokyo, Seoul or Singapore what the rules are for using a machine learning model in a drug submission, and the honest answe...
October 22, 2026 | Analysis
Every October, the same headline writes itself. India leads the count of US FDA warning letters to Asian drug plants, China follows, and the rest of the re...
October 21, 2026 | Analysis
Most Read
Bio Jobs
News